Version 3 2022-03-02, 03:02Version 3 2022-03-02, 03:02
Version 2 2022-03-01, 00:43Version 2 2022-03-01, 00:43
Version 1 2022-02-22, 23:34Version 1 2022-02-22, 23:34
journal contribution
posted on 2022-03-02, 03:02authored byGeraldine VaughanGeraldine Vaughan, Angela Dawson, Michael Peek, Karen Sliwa, Jonathan Carapetis, Vicki Wade, Elizabeth Sullivan
RHD in pregnancy (RHD-P) is associated with an increased burden of maternal and perinatal morbidity and mortality. A sequellae of rheumatic fever resulting in heart valve damage if untreated, RHD is twice as common in women. In providing an historical overview, this commentary provides context for prevention and treatment in the 21 st century. Four underlying themes inform much of the literature on RHD-P: its association with inequities; often-complex care requirements; demands for integrated care models, and a life-course approach. While there have been some gains particularly in awareness, strengthened policies and funding strategies are required to sustain improvements in the RHD landscape and consequently improve outcomes. As the principal heart disease seen in pregnant women in endemic regions, it is unlikely that the Sustainable Development Goal 3 target of reduced global maternal mortality ratio can be met by 2030 if RHD is not better addressed for women and girls.
Funding
Category 1 - Australian Competitive Grants (this includes ARC, NHMRC)
This research output may contain the names and images of Aboriginal and Torres Strait Islander people now deceased. We apologize for any distress that may occur.
Acceptance Date
2021-09-30
External Author Affiliations
The University of Newcastle; University of Cape Town; University of Western Australia; Menzies School of Health Research, NT; University of Technology Sydney; The Australian National University